Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies
Jorge Calderón‐Parra, Elena Múñez, Ana Fernández‐Cruz, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 10, pp. 1786-1794
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Comorbidities, multimorbidity and COVID-19
Clark D Russell, Nazir Lone, J. Kenneth Baillie
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 334-343
Open Access | Times Cited: 233
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin C. Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 88
Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study
Sung‐Woon Kang, Jun-Won Kim, Ji Yeun Kim, et al.
Journal of Infection (2023) Vol. 86, Iss. 4, pp. 412-414
Open Access | Times Cited: 29
Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and management
Suzy Meijer, Yael Paran, Ana Belkin, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 1012-1017
Closed Access | Times Cited: 11
Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study
Jorge Calderón‐Parra, Andrea Gutiérrez-Villanueva, Gerard Ronda-Roca, et al.
International Journal of Antimicrobial Agents (2024) Vol. 63, Iss. 3, pp. 107095-107095
Open Access | Times Cited: 8
The unique presentation of SARS-CoV-2 Infection in patients with B-cell depletion: definition of ‘persistent inflammatory sero-negative COVID’
Ana Belkin, Avshalom Leibowitz, Liat Shargian, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 1, pp. 1-3
Open Access | Times Cited: 27
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors
Sarah Dybowski, Sebastian Torke, Martin S. Weber
JAMA Neurology (2023) Vol. 80, Iss. 4, pp. 404-404
Closed Access | Times Cited: 16
Early initiation of combined therapy in severely immunocompromised patients with COVID-19: a retrospective cohort study
Salvatore Rotundo, Lavinia Berardelli, Sara Palma Gullì, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Situación actual de la inmunización pasiva frente al COVID en los pacientes respiratorios
Víctor Manuel Mora Cuesta, Beatríz Arana Gómez, Raquel Pérez Rojo
Open Respiratory Archives (2025) Vol. 7, Iss. 2, pp. 100398-100398
Open Access
Efficacy of antiviral therapy and disease outcomes in COVID-19 patients previously treated with obinutuzumab for follicular lymphoma
Nobuhiro Okagaki, Seishu Hashimoto, Satoshi N. Nakamura, et al.
Tenri Medical Bulletin (2025)
Open Access
Successful 30-Day Nirmatrelvir/Ritonavir Treatment of a Patient Who Developed Multi-relapsed COVID-19 After Receiving R-CHOP Against Follicular Lymphoma
Kou Kimoto, Hitoshi Kawasuji, Yoshihiro Yoshida, et al.
Cureus (2025)
Open Access
Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study
Jennifer H. Ku, Lina S. Sy, Lei Qian, et al.
Vaccine (2023) Vol. 41, Iss. 24, pp. 3636-3646
Open Access | Times Cited: 13
An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab
Tali Shafat, Daniel Grupel, Tzvika Porges, et al.
Cancer Medicine (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 4
Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID‐19
Tali Shafat, Daniel Grupel, Tzvika Porges, et al.
British Journal of Haematology (2022) Vol. 198, Iss. 5, pp. 826-829
Open Access | Times Cited: 18
Clinical and genomic evaluations of a persistent fatal SARS-CoV-2 infection in a goods syndrome patient: a case report
Payam Tabarsi, Ali Maleki, Zahra Abtahian, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
Maike Janssen, Albrecht Leo, Cornelia Wolf, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 4, pp. 618-626
Open Access | Times Cited: 3
Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry
Jorge Calderón‐Parra, Valentín Cuervas‐Mons, Víctor Moreno‐Torres, et al.
International Journal of Infectious Diseases (2021) Vol. 116, pp. 51-58
Open Access | Times Cited: 21
Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab
Antoine Morel, Sandrine Imbeaud, Anne Scemla, et al.
American Journal of Transplantation (2022) Vol. 22, Iss. 8, pp. 2099-2103
Open Access | Times Cited: 15
COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response
Ivan Gur, Amir Giladi, Yonathan Nachum Isenberg, et al.
Acta Haematologica (2022) Vol. 145, Iss. 3, pp. 297-309
Open Access | Times Cited: 15
Relapsing COVID-19 infection as a manifestation of Good syndrome: a case report and literature review
Liang En Wee, Jing Yuan Tan, Lynette Lin Ean Oon, et al.
International Journal of Infectious Diseases (2023) Vol. 129, pp. 236-239
Open Access | Times Cited: 8
Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort
Jorge Calderón‐Parra, Pablo Guisado‐Vasco, Rocío Montejano-Sánchez, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 864-864
Open Access | Times Cited: 8
Persistent SARS-CoV-2 infection in patients with B-cell deficiency: a case series of successful antiviral treatment of four patients
Lisa Faxén, Marie Edvinsson
Upsala Journal of Medical Sciences (2023) Vol. 128
Open Access | Times Cited: 8
Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases
Igor Aurer, Ozren Jakšić, Sandra Bašić‐Kinda, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 331-331
Open Access | Times Cited: 2
ATUALIZAÇÕES EM PROMOÇÃO DA SAÚDE
Paulo Sérgio da Paz Silva Filho, Lennara Pereira Mota
(2024)
Open Access | Times Cited: 2
COVID-19 mortality amongst the immunosuppresed
Víctor Moreno‐Torres, María Martínez‐Urbistondo, Jorge Calderón‐Parra, et al.
Journal of Infection (2024) Vol. 88, Iss. 4, pp. 106137-106137
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top